Publications

Publications 2017-10-13T10:01:59+00:00

  1. Larsen, P.A., M.W. Lutz, K.E. Hunnicutt, M. Mihovilovic, A.M. Saunders, A.D. Yoder, and A.D. Roses, The Alu neurodegeneration hypothesis: A primate-specific mechanism for neuronal transcription noise, mitochondrial dysfunction, and manifestation of neurodegenerative disease. Alzheimers Dement, 2017.
  2. Roses, A.D., P.A. Akkari, O. Chiba-Falek, M.W. Lutz, W.K. Gottschalk, A.M. Saunders, B. Saul, S. Sundseth, and D. Burns, Structural variants can be more informative for disease diagnostics, prognostics and translation than current SNP mapping and exon sequencing. Expert Opin Drug Metab Toxicol, 2016. 12(2): p. 135-47.
  3. Roses, A., S. Sundseth, A. Saunders, W. Gottschalk, D. Burns, and M. Lutz, Understanding the genetics of APOE and TOMM40 and role of mitochondrial structure and function in clinical pharmacology of Alzheimer's disease. Alzheimers Dement, 2016. 12(6): p. 687-94.
  4. Mega, J.L., S.L. Close, S.D. Wiviott, M. Man, S. Duvvuru, J.R. Walker, S.S. Sundseth, J.P. Collet, J.T. Delaney, J.S. Hulot, S.A. Murphy, G. Pare, M.J. Price, D. Sibbing, T. Simon, D. Trenk, E.M. Antman, and M.S. Sabatine, PON1 Q192R genetic variant and response to clopidogrel and prasugrel: pharmacokinetics, pharmacodynamics, and a meta-analysis of clinical outcomes. J Thromb Thrombolysis, 2016. 41(3): p. 374-83.
  5. Lutz, M.W., S.S. Sundseth, D.K. Burns, A.M. Saunders, K.M. Hayden, J.R. Burke, K.A. Welsh-Bohmer, and A.D. Roses, A Genetics-based Biomarker Risk Algorithm for Predicting Risk of Alzheimer's Disease. Alzheimers Dement (N Y), 2016. 2(1): p. 30-44.
  6. Doll, J.A., M.L. Neely, M.T. Roe, P.W. Armstrong, H.D. White, D. Prabhakaran, K.J. Winters, S. Duvvuru, S.S. Sundseth, J.A. Jakubowski, P.A. Gurbel, D.L. Bhatt, E.M. Ohman, K.A. Fox, and T.A. Investigators, Impact of CYP2C19 Metabolizer Status on Patients With ACS Treated With Prasugrel Versus Clopidogrel. J Am Coll Cardiol, 2016. 67(8): p. 936-47.
  7. Larsen, M.E., L. Curry, N. Mastellos, C. Robb, J. Car, and L.T. Middleton, Development of the CHARIOT Research Register for the Prevention of Alzheimer’s Dementia and Other Late Onset Neurodegenerative Diseases. PLOS ONE, 2015. 10(11): p. e0141806.
  8. Bishop, J.P., S.B. Halburnt, P.A. Akkari, S. Sundseth, and I. Grossman, Roadmap to Drug Development Enabled by Pharmacogenetics, in Preventive and Predictive Genetics: Towards Personalised Medicine, G. Grech and I. Grossman, Editors. 2015, Springer International Publishing. p. 43-67.
  9. Wong, C.J., J. Witcher, C. Mallinckrodt, R.A. Dean, R.F. Anton, Y. Chen, B.A. Fijal, H. Ouyang, S. Dharia, S.S. Sundseth, K.J. Schuh, and B.J. Kinon, A phase 2, placebo-controlled study of the opioid receptor antagonist LY2196044 for the treatment of alcohol dependence. Alcohol Clin Exp Res, 2014. 38(2): p. 511-20.
  10. Swanson, T.W., P.A. Akkari, J.A. Arbuckle, I. Grossman, S.S. Sundseth, and A.D. Roses, Methodology to Enable Integration of Genomic Knowledge into Drug Development, in Handbook of Personalized Medicine: Advances in Drug Delivery and Therapy. 2014, Pan Stanford Publishing: Singapore. p. 645-684.
  11. Roses, A.D., A.M. Saunders, M.W. Lutz, N. Zhang, A.R. Hariri, K.E. Asin, D.G. Crenshaw, K. Budur, D.K. Burns, and S.K. Brannan, New applications of disease genetics and pharmacogenetics to drug development. Curr Opin Pharmacol, 2014. 14: p. 81-9.
  12. Roses, A.D., M.W. Lutz, A.M. Saunders, D. Goldgaber, R. Saul, S.S. Sundseth, P.A. Akkari, S.M. Roses, W.K. Gottschalk, K.E. Whitfield, A.A. Vostrov, M.A. Hauser, R.R. Allingham, D.K. Burns, O. Chiba-Falek, and K.A. Welsh-Bohmer, African-American TOMM40'523-APOE haplotypes are admixture of West African and Caucasian alleles. Alzheimers Dement, 2014. 10(6): p. 592-601 e2.
  13. Romero, H.R., K.A. Welsh-Bohmer, L.P. Gwyther, H.L. Edmonds, B.L. Plassman, C.M. Germain, M. McCart, K.M. Hayden, C. Pieper, and A.D. Roses, Community engagement in diverse populations for Alzheimer’s disease prevention trials. Alzheimer disease and associated disorders, 2014. 28(3): p. 269-274.
  14. Lyall, D.M., S.E. Harris, M.E. Bastin, S. Munoz Maniega, C. Murray, M.W. Lutz, A.M. Saunders, A.D. Roses, C. Valdes Hernandez Mdel, N.A. Royle, J.M. Starr, D.J. Porteous, J.M. Wardlaw, and I.J. Deary, Alzheimer's disease susceptibility genes APOE and TOMM40, and brain white matter integrity in the Lothian Birth Cohort 1936. Neurobiol Aging, 2014. 35(6): p. 1513 e25-33.
  15. Hayden, K.M., O.A. Makeeva, L.K. Newby, B.L. Plassman, V.V. Markova, A. Dunham, H.R. Romero, Z.A. Melikyan, C.M. Germain, K.A. Welsh-Bohmer, and A.D. Roses, A comparison of neuropsychological performance between US and Russia: Preparing for a global clinical trial. Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2014. 10(6): p. 760-768.e1.
  16. Gurbel, P.A., T.O. Bergmeijer, U.S. Tantry, J.M. ten Berg, D.J. Angiolillo, S. James, T.L. Lindahl, P. Svensson, J.A. Jakubowski, P.B. Brown, S. Duvvuru, S. Sundseth, J.R. Walker, D. Small, B.A. Moser, K.J. Winters, and D. Erlinge, The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease. Thromb Haemost, 2014. 112(3): p. 589-97.
  17. Greenbaum, L., R.R. Springer, M.W. Lutz, A. Heymann, I. Lubitz, I. Cooper, E. Kravitz, M. Sano, A.D. Roses, J.M. Silverman, A.M. Saunders, and M.S. Beeri, The TOMM40 poly-T rs10524523 variant is associated with cognitive performance among non-demented elderly with type 2 diabetes. Eur Neuropsychopharmacol, 2014. 24(9): p. 1492-9.
  18. Gottschalk, W.K., M.W. Lutz, Y.T. He, A.M. Saunders, D.K. Burns, A.D. Roses, and O. Chiba-Falek, The Broad Impact of TOM40 on Neurodegenerative Diseases in Aging. J Parkinsons Dis Alzheimers Dis, 2014. 1(1).
  19. Erlinge, D., S. James, S. Duvvuru, J.A. Jakubowski, H. Wagner, C. Varenhorst, U.S. Tantry, P.B. Brown, D. Small, B.A. Moser, S.S. Sundseth, J.R. Walker, K.J. Winters, and P.A. Gurbel, Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease. Thromb Haemost, 2014. 111(5): p. 943-50.
  20. Diodati, J.G., J.F. Saucedo, T.E. Cardillo, J.A. Jakubowski, C. Henneges, M.B. Effron, F.R. Lipkin, J.R. Walker, S. Duvvuru, S.S. Sundseth, H.N. Fisher, and D.J. Angiolillo, Transferring from clopidogrel loading dose to prasugrel loading dose in acute coronary syndrome patients. High on-treatment platelet reactivity analysis of the TRIPLET trial. Thromb Haemost, 2014. 112(2): p. 311-22.
  21. Roses, A.D., M.W. Lutz, D.G. Crenshaw, I. Grossman, A.M. Saunders, and W.K. Gottschalk, TOMM40 and APOE: Requirements for replication studies of association with age of disease onset and enrichment of a clinical trial. Alzheimers Dement, 2013. 9(2): p. 132-6.
  22. Crenshaw, D.G., W.K. Gottschalk, M.W. Lutz, I. Grossman, A.M. Saunders, J.R. Burke, K.A. Welsh-Bohmer, S.K. Brannan, D.K. Burns, and A.D. Roses, Using genetics to enable studies on the prevention of Alzheimer's disease. Clin Pharmacol Ther, 2013. 93(2): p. 177-85.
  23. Braun, O.O., D.J. Angiolillo, J.L. Ferreiro, J.A. Jakubowski, K.J. Winters, M.B. Effron, S. Duvvuru, T.M. Costigan, S. Sundseth, J.R. Walker, J.F. Saucedo, N.S. Kleiman, and C. Varenhorst, Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways. Thromb Haemost, 2013. 110(6): p. 1223-31.
  24. Linnertz, C., A.M. Saunders, M.W. Lutz, D.M. Crenshaw, I. Grossman, D.K. Burns, K.E. Whitfield, M.A. Hauser, J.J. McCarthy, M. Ulmer, R. Allingham, K.A. Welsh-Bohmer, A.D. Roses, and O. Chiba-Falek, Characterization of the poly-T variant in the TOMM40 gene in diverse populations. PLoS One, 2012. 7(2): p. e30994.
  25. Burns, D.K. and S.S. Sundseth, Applications of Pharmacogenetics in Pharmaceutical Research and Development, in Pharmacogenetics and Individualized Therapy. 2012, John Wiley & Sons, Inc. p. 437-460.
  26. Lutz, M.W., D.G. Crenshaw, A.M. Saunders, and A.D. Roses, The importance of being connected. J Alzheimers Dis, 2011. 24(2): p. 247-51.
  27. Johnson, S.C., A. La Rue, B.P. Hermann, G. Xu, R.L. Koscik, E.M. Jonaitis, B.B. Bendlin, K.J. Hogan, A.D. Roses, A.M. Saunders, M.W. Lutz, S. Asthana, R.C. Green, and M.A. Sager, The effect of TOMM40 poly-T length on gray matter volume and cognition in middle-aged persons with APOE epsilon3/epsilon3 genotype. Alzheimers Dement, 2011. 7(4): p. 456-65.
  28. Roses, A.D., M.W. Lutz, H. Amrine-Madsen, A.M. Saunders, D.G. Crenshaw, S.S. Sundseth, M.J. Huentelman, K.A. Welsh-Bohmer, and E.M. Reiman, A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's disease. Pharmacogenomics J, 2010. 10(5): p. 375-84.
  29. Lutz, M.W., D.G. Crenshaw, A.M. Saunders, and A.D. Roses, Genetic variation at a single locus and age of onset for Alzheimer's disease. Alzheimers Dement, 2010. 6(2): p. 125-31.
  30. Grossman, I., M.W. Lutz, D.G. Crenshaw, A.M. Saunders, D.K. Burns, and A.D. Roses, Alzheimer's disease: diagnostics, prognostics and the road to prevention. EPMA J, 2010. 1(2): p. 293-303.
  31. Gold, M., C. Alderton, M. Zvartau-Hind, S. Egginton, A.M. Saunders, M. Irizarry, S. Craft, G. Landreth, U. Linnamagi, and S. Sawchak, Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study. Dement Geriatr Cogn Disord, 2010. 30(2): p. 131-46.
  32. Roses, A.D., Stimulation of Cholecystokinin-A Receptors With Gl181771X: A Failed Clinical Trial That Did Not Test the Pharmacogenetic Hypothesis for Reduction of Food Intake. Clinical Pharmacology & Therapeutics, 2009. 85(4): p. 362-365.
  33. Lin, X., K. Song, N. Lim, X. Yuan, T. Johnson, A. Abderrahmani, P. Vollenweider, H. Stirnadel, S.S. Sundseth, E. Lai, D.K. Burns, L.T. Middleton, A.D. Roses, P.M. Matthews, G. Waeber, L. Cardon, D.M. Waterworth, and V. Mooser, Risk prediction of prevalent diabetes in a Swiss population using a weighted genetic score--the CoLaus Study. Diabetologia, 2009. 52(4): p. 600-8.
  34. Akkari, P.A., T.W. Swanson, D.G. Crenshaw, I. Grossman, S. Sundseth, D.K. Burns, and A.D. Roses, Pipeline pharmacogenetics: a novel approach to integrating pharmaco-genetics into drug development. Curr Pharm Des, 2009. 15(32): p. 3754-63.
  35. Pharmaceuticals, E.L.-C., Cabernet Pharmaceuticals and Lilly Form Pharmacogenetics Alliance to Help Deliver Tailored Therapeutics to Patients. 2008.
  36. Mallal , S., E. Phillips , G. Carosi , J.-M. Molina , C. Workman , J. Tomažič , E. Jägel-Guedes , S. Rugina , O. Kozyrev , J.F. Cid , P. Hay , D. Nolan , S. Hughes , A. Hughes , S. Ryan , N. Fitch , D. Thorborn , and A. Benbow HLA-B*5701 Screening for Hypersensitivity to Abacavir. New England Journal of Medicine, 2008. 358(6): p. 568-579.
  37. Cogswell, J.P., J. Ward, I.A. Taylor, M. Waters, Y. Shi, B. Cannon, K. Kelnar, J. Kemppainen, D. Brown, C. Chen, R.K. Prinjha, J.C. Richardson, A.M. Saunders, A.D. Roses, and C.A. Richards, Identification of miRNA changes in Alzheimer's disease brain and CSF yields putative biomarkers and insights into disease pathways. J Alzheimers Dis, 2008. 14(1): p. 27-41.
  38. Akuffo, E.L., J.B. Davis, S.M. Fox, I.S. Gloger, D. Hosford, E.E. Kinsey, N.A. Jones, C.M. Nock, A.D. Roses, A.M. Saunders, J.M. Skehel, M.A. Smith, and P. Cutler, The discovery and early validation of novel plasma biomarkers in mild-to-moderate Alzheimer's disease patients responding to treatment with rosiglitazone. Biomarkers, 2008. 13(6): p. 618-36.
  39. Kraus, V.B., J.M. Jordan, M. Doherty, A.G. Wilson, R. Moskowitz, M. Hochberg, R. Loeser, M. Hooper, J.B. Renner, M.M. Crane, P. Hastie, S. Sundseth, and U. Atif, The Genetics of Generalized Osteoarthritis (GOGO) study: study design and evaluation of osteoarthritis phenotypes. Osteoarthritis Cartilage, 2007. 15(2): p. 120-7.
  40. Adamo, K.B., R. Dent, C.D. Langefeld, M. Cox, K. Williams, K.M. Carrick, J.S. Stuart, S.S. Sundseth, M.E. Harper, R. McPherson, and F. Tesson, Peroxisome proliferator-activated receptor gamma 2 and acyl-CoA synthetase 5 polymorphisms influence diet response. Obesity (Silver Spring), 2007. 15(5): p. 1068-75.
  41. Risner, M.E., A.M. Saunders, J.F. Altman, G.C. Ormandy, S. Craft, I.M. Foley, M.E. Zvartau-Hind, D.A. Hosford, A.D. Roses, and G. Rosiglitazone in Alzheimer's Disease Study, Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J, 2006. 6(4): p. 246-54.
  42. Yu, Y., D.F. Wyszynski, D.M. Waterworth, S.D. Wilton, P.J. Barter, Y.A. Kesaniemi, R.W. Mahley, R. McPherson, G. Waeber, T.P. Bersot, Q. Ma, S.S. Sharma, D.S. Montgomery, L.T. Middleton, S.S. Sundseth, V. Mooser, S.M. Grundy, and L.A. Farrer, Multiple QTLs influencing triglyceride and HDL and total cholesterol levels identified in families with atherogenic dyslipidemia. J Lipid Res, 2005. 46(10): p. 2202-13.
  43. Wyszynski, D.F., D.M. Waterworth, P.J. Barter, J. Cohen, Y.A. Kesaniemi, R.W. Mahley, R. McPherson, G. Waeber, T.P. Bersot, S.S. Sharma, V. Nolan, L.T. Middleton, S.S. Sundseth, L.A. Farrer, V. Mooser, and S.M. Grundy, Relation between atherogenic dyslipidemia and the Adult Treatment Program-III definition of metabolic syndrome (Genetic Epidemiology of Metabolic Syndrome Project). Am J Cardiol, 2005. 95(2): p. 194-8.
  44. Ahmadi, K.R., M.E. Weale, Z.Y. Xue, N. Soranzo, D.P. Yarnall, J.D. Briley, Y. Maruyama, M. Kobayashi, N.W. Wood, N.K. Spurr, D.K. Burns, A.D. Roses, A.M. Saunders, and D.B. Goldstein, A single-nucleotide polymorphism tagging set for human drug metabolism and transport. Nat Genet, 2005. 37(1): p. 84-9.
  45. Roses, A.D., Pharmacogenetics and drug development: the path to safer and more effective drugs. Nat Rev Genet, 2004. 5(9): p. 645-656.
  46. Reiman, E.M., K. Chen, G.E. Alexander, R.J. Caselli, D. Bandy, D. Osborne, A.M. Saunders, and J. Hardy, Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci U S A, 2004. 101(1): p. 284-9.
  47. Kraus, V.B., Y.J. Li, E.R. Martin, J.M. Jordan, J.B. Renner, M. Doherty, A.G. Wilson, R. Moskowitz, M. Hochberg, R. Loeser, M. Hooper, and S. Sundseth, Articular hypermobility is a protective factor for hand osteoarthritis. Arthritis Rheum, 2004. 50(7): p. 2178-83.
  48. Hauser, E.R., D.C. Crossman, C.B. Granger, J.L. Haines, C.J. Jones, V. Mooser, B. McAdam, B.R. Winkelmann, A.H. Wiseman, J.B. Muhlestein, A.G. Bartel, C.A. Dennis, E. Dowdy, S. Estabrooks, K. Eggleston, S. Francis, K. Roche, P.W. Clevenger, L. Huang, B. Pedersen, S. Shah, S. Schmidt, C. Haynes, S. West, D. Asper, M. Booze, S. Sharma, S. Sundseth, L. Middleton, A.D. Roses, M.A. Hauser, J.M. Vance, M.A. Pericak-Vance, and W.E. Kraus, A genomewide scan for early-onset coronary artery disease in 438 families: the GENECARD Study. Am J Hum Genet, 2004. 75(3): p. 436-47.
  49. Root, C., C.D. Smith, S.S. Sundseth, H.M. Pink, J.G. Wilson, and M.C. Lewis, Ileal bile acid transporter inhibition, CYP7A1 induction, and antilipemic action of 264W94. J Lipid Res, 2002. 43(8): p. 1320-30.
  50. Way, J.M., W.W. Harrington, K.K. Brown, W.K. Gottschalk, S.S. Sundseth, T.A. Mansfield, R.K. Ramachandran, T.M. Willson, and S.A. Kliewer, Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor gamma activation has coordinate effects on gene expression in multiple insulin-sensitive tissues. Endocrinology, 2001. 142(3): p. 1269-77.
  51. Saunders, A.M., Gene identification in Alzheimer's disease. Pharmacogenomics, 2001. 2(3): p. 239-49.
  52. Gould Rothberg, B.E., S.S. Sundseth, V.A. DiPippo, P.J. Brown, D.A. Winegar, W.K. Gottshalk, S.G. Shenoy, and J.M. Rothberg, The characterization of PPAR alpha ligand drug action in an in vivo model by comprehensive differential gene expression profiling. Funct Integr Genomics, 2001. 1(5): p. 294-304.
  53. Saunders, A.M., M.K. Trowers, R.A. Shimkets, S. Blakemore, D.J. Crowther, T.A. Mansfield, D.M. Wallace, W.J. Strittmatter, and A.D. Roses, The role of apolipoprotein E in Alzheimer's disease: pharmacogenomic target selection. Biochim Biophys Acta, 2000. 1502(1): p. 85-94.
  54. Bookheimer, S.Y., M.H. Strojwas, M.S. Cohen, A.M. Saunders, M.A. Pericak-Vance, J.C. Mazziotta, and G.W. Small, Patterns of brain activation in people at risk for Alzheimer's disease. N Engl J Med, 2000. 343(7): p. 450-6.
  55. Brown, P.J., D.A. Winegar, K.D. Plunket, L.B. Moore, M.C. Lewis, J.G. Wilson, S.S. Sundseth, C.S. Koble, Z. Wu, J.M. Chapman, J.M. Lehmann, S.A. Kliewer, and T.M. Willson, A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPARalpha agonist with potent lipid-lowering activity. J Med Chem, 1999. 42(19): p. 3785-8.
  56. Mayeux, R., A.M. Saunders, S. Shea, S. Mirra, D. Evans, A.D. Roses, B.T. Hyman, B. Crain, M.X. Tang, and C.H. Phelps, Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. N Engl J Med, 1998. 338(8): p. 506-11.
  57. Hulette, C.M., K.A. Welsh-Bohmer, M.G. Murray, A.M. Saunders, D.C. Mash, and L.M. McIntyre, Neuropathological and neuropsychological changes in "normal" aging: evidence for preclinical Alzheimer disease in cognitively normal individuals. J Neuropathol Exp Neurol, 1998. 57(12): p. 1168-74.
  58. Lehmann, J.M., S.A. Kliewer, L.B. Moore, T.A. Smith-Oliver, B.B. Oliver, J.L. Su, S.S. Sundseth, D.A. Winegar, D.E. Blanchard, T.A. Spencer, and T.M. Willson, Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J Biol Chem, 1997. 272(6): p. 3137-40.
  59. Kliewer, S.A., S.S. Sundseth, S.A. Jones, P.J. Brown, G.B. Wisely, C.S. Koble, P. Devchand, W. Wahli, T.M. Willson, J.M. Lenhard, and J.M. Lehmann, Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci U S A, 1997. 94(9): p. 4318-23.